

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	ADAM10; ADAM17	<i>In vitro</i> studies suggest inhibiting ADAM10 and ADAM17 could help stimulate an NK cell immune response to treat cancer. In cultured cancer cell lines, ADAM inhibitors or siRNAs targeting ADAM10 or ADAM17 increased cell surface expression of an NK cell target, B7-H6 tumor cell ligand, compared with vehicle or control siRNAs. Next steps include evaluating the effect of ADAM10 and ADAM17 inhibitors in animal models.	Patent and licensing status unavailable	Schlecker, E. <i>et al. Cancer Res.</i> ; published online April 29, 2014; doi:10.1158/0008-5472.CAN-13-3017 <b>Contact:</b> Adelheid Cerwenka, German Cancer Research Center, Heidelberg, Germany e-mail: <a href="mailto:a.cerwenka@dkfz.de">a.cerwenka@dkfz.de</a>
		<i>SciBX</i> 7(23); doi:10.1038/scibx.2014.669 Published online June 12, 2014		